MedTrace Logo

Role of the IL33/Amphiregulin Pathway as a Potential Therapeutic Target in HIV Infection

NCT03622177 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2018-08-09

No results posted yet for this study

Summary

Interleukin33 organize local immune reactions, especially at epithelial barriers.

ST2 is the IL33 receptor. The sST2 rate is higher for patient living with HIV and is an independent predictable factor of mortality. Interleukin33 induce tissue Treg ST2+ lymphocytes proliferation and amphireguline production. Amphireguline is member of epithelial growth factors family, which contributes to tissue repair, and fibrose. Amphireguline also helps immunosuppressives functions. Targetting amphiregulin for people living with HIV who has poor restauration of LTCD4+ could be a future therapy.

Conditions

  • HIV I Infection

Interventions

PROCEDURE

biopsie

Additional colorectal mucosal biopsies during rectoscopy or colonoscopy

BIOLOGICAL

blood drawn

Additional blood drawn by venepuncture

Sponsors & Collaborators

  • ANRS, Emerging Infectious Diseases

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-30
Primary Completion
2019-09-30
Completion
2023-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03622177 on ClinicalTrials.gov